Un grand avenir pour le vieillissement - IPO
Biophytis a développé une plateforme de candidats médicaments dérivés de molécules naturelles, auxquelles l’organisme est déjà naturellement exposé par l’alimentation (phytonutriments) et qui offrent donc a priori un profil pharmacologique favorable. Biophytis cible les pathologies liées au vieillissement, en particulier les processus de dégénérescence du muscle ou de la rétine. Deux produits, dans la DMLA forme sèche (Dégénérescence maculaire liée à l’âge) et dans l’Obésité sarcopénique entrent en phase IIb d’essais cliniques en 2015. Ils visent des stades intermédiaires de pathologies pour lesquelles il n’existe aucun traitement sur des marchés de plusieurs Mds€. La stratégie de Biophytis est de licencier ces produits après preuve de concept clinique en 2017 et 2018.Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.